### 1 Mycobacteria-host interactions in human bronchiolar airway

### 2 organoids

- 3 Nino lakobachvili<sup>1</sup>, Stephen Adonai Leon Icaza<sup>2</sup>, Kèvin Knoops<sup>1</sup>, Norman
- 4 Sachs<sup>3</sup>, Serge Mazères<sup>2</sup>, Roxane Simeone<sup>4</sup>, Antonio Peixoto<sup>2</sup>, Marlène Murris-
- 5 Espin<sup>5</sup>, Julien Mazières<sup>5</sup>, Carmen López-Iglesias<sup>1</sup>, Raimond B.G. Ravelli<sup>1</sup>, Olivier
- 6 Neyrolles<sup>2,6</sup>, Etienne Meunier<sup>2</sup>, Geanncarlo Lugo-Villarino<sup>2,6</sup>, Hans Clevers<sup>3</sup>,
- 7 Céline Cougoule<sup>2,6,7\*</sup>, Peter J. Peters<sup>1,7\*</sup>
- 8
- <sup>9</sup> <sup>1</sup> M4i Nanoscopy Division, Maastricht University, Maastricht, Netherlands
- <sup>2</sup> Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse,
- 11 CNRS, UPS, Toulouse, France
- <sup>12</sup> <sup>3</sup> Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and
- 13 Sciences and University Medical Center, Utrecht, Netherlands
- <sup>4</sup> Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, CNRS
- 15 UMR3525, Paris, France
- <sup>16</sup> <sup>5</sup> Service de Pneumologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France
- <sup>17</sup> <sup>6</sup>International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse,
- 18 France and Buenos Aires, Argentina
- <sup>19</sup> <sup>7</sup> These authors contributed equally to this work.
- 20
- 21 **\*Corresponding authors:**
- 22 Email: pj.peters@maastrichtuniversity.nl ; Celine.Cougoule@ipbs.fr
- 23
- 24

### 25 Author Contributions

NI, CC and PJP designed the experiments with the help of CLI, ON, EM and GLV.
NI, SALI and CC performed the experiments with the contribution of KK, RBGR,
SM and AP. SR generated the fluorescent Mtb strains. MME and JM provided the
lung biopsies. HC and NS developed the lung organoid technology. NI, CC and
PJP wrote the manuscript.

31

32 Competing Interest Statement: H.C and N.S are inventors on patents related to
 33 organoid technology.

34

#### 35 Abstract

36 Tuberculosis, one of the oldest human pathogens remains a major global health threat. Recent advances in organoid technology offer a unique opportunity to grow 37 different human "organs" in vitro, including the human airway, that faithfully 38 39 recapitulate tissue architecture and function. We have explored the potential of 40 human airway organoids (AOs) as a novel system in which to model tuberculosis 41 infection. To this end, we adapted biosafety containment level 3-approved 42 procedures to allow successful microinjection of *Mycobacterium tuberculosis*, the 43 causative agent of tuberculosis, into AOs. We reveal that mycobacteria infected 44 epithelial cells with low efficiency, and that the organoid microenvironment was 45 able to control, but not eliminate the pathogen. We demonstrate that AOs 46 responded to infection by inducing cytokine and antimicrobial peptide production, 47 and inhibiting mucins. Given the importance of myeloid cells in tuberculosis 48 infection, we co-cultured mycobacteria-infected organoids with human monocyte-

- 49 derived macrophages, and found that these cells were recruited to the organoid
- 50 epithelium. We conclude that adult stem cell-derived airway organoids can be
- 51 used to model early events of tuberculosis infection and offer new avenues for
- 52 fundamental and therapeutic research.

#### 53 Introduction

Airborne pathogens are a major cause of death worldwide. Respiratory infectious diseases cause more than 5 million fatalities annually, with tuberculosis (TB) accounting for one-fifth (WHO Global tuberculosis report 2019). In 2018, TB caused an estimated 1.5 million deaths, making TB one of the top 10 killers worldwide, and 25% of the worlds population is thought to be latently infected by *Mycobacterium tuberculosis* (Mtb) (1).

The lung is the entry port for Mtb and the main site of TB disease 60 manifestation. Mtb-containing droplets navigate through the lung anatomy and 61 airway functions in order for mycobacteria to establish its replicative niche in the 62 63 alveolar space (2, 3). Models of human lung infection are therefore crucial to 64 increase our understanding of host-pathogen interactions- an essential step 65 towards new drug development. Whilst conventional 2D cell culture and animal 66 models have contributed to deciphering key host-pathogen mechanisms at play 67 during Mtb infection (4), they lack relevance with the human lung.

One of the major breakthroughs in the stem cell field is the ability to grow 68 69 human 'organs' in vitro, also known as organoids (5). Human airway organoids 70 (AOs) are derived from adult stem-cells and composed of a polarized, 71 pseudostratified airway epithelium containing basal, secretory and multi-ciliated 72 cells, although they are currently lacking alveolar pneumocytes. They display 73 functional mucus secretion and ciliate beating (6), therefore constituting a suitable 74 human system in which to model early steps of host-pathogen interactions (7-9). 75 We have set out to evaluate the potential of AOs as a model in which to study Mtb 76 infection. Our data demonstrate that mycobacteria can be readily found in the Iumen of AOs with some internalization by airway epithelial cells and overall control of mycobacterial growth. In response to Mtb infection, we show AOs inducing the secretion of cytokines and antimicrobial peptides, and the option to model innate cell recruitment by co-culturing human macrophages with injected AOs.

81

#### 82 **Results & Discussion**

83 Due to the innate cystic structure of AOs, where the pathogen-sensing apical side 84 faces the lumen, DsRed-expressing H37Rv Mtb (mean 4271±834 CFU/organoid) 85 was microinjected via a BSL-3-approved custom-made micro-injection system (Figure 1A). Bacteria could be found in the lumen of AOs and occasionally making 86 87 contact with epithelial cells but without causing obvious alterations to organoid 88 architecture and ultrastructure (Figure 1B-C, Movie S1 and S2). Evident from the movies is the functional mucociliary system where cilia beat secreted mucus and 89 90 cell debris around the lumen.

91 Mtb is known to infect bronchial epithelial cells in 2D conditions (10), and 92 pneumocytes in vitro (11) and in vivo (12), but with low efficiency. To identify if Mtb 93 could infect organoid derived epithelial cells, AOs were dissociated into single 94 cells, infected with Mtb H37Rv and analyzed by flow cytometry. Approximately 95 13% and 19% of epithelial cells were found associated with bacteria after 4 h and 96 24 h of infection, respectively (Figure 1D). Sorted epithelial cells showed that 97 individual cells harboured Mtb (Figure 1E) suggesting cell invasion by a yet 98 unknown mechanism. The number of internalised bacteria dropped to 2% when 99 AOs, which had been infected with Mtb for 7 days, were dissociated into single 100 cells and analyzed by flow cytometry (Figure 1D). The functioning mucociliary 101 clearance system within AOs is likely responsible for reducing mycobacterial102 contact with epithelial cells.

103 Mtb has a functional type VII secretion system (ESX-1) encoded by the RD1 104 locus which is involved in modulating host responses and inducing host cell lysis 105 (13-16). To determine whether the presence of ESX-1 induced increased epithelial 106 cell lysis, we quantified cell death by TOPRO-3 incorporation in AOs after injection 107 of wild-type H37Rv or H37Rv ESX-1 which lacks ESX-1. Neither strain induced 108 significant epithelial cell death in Mtb-infected AOs compared to uninfected ones 109 (Supp. Figure 1A), indicating that a functional ESX-1 expression does not trigger 110 increased epithelial cell damage.

Next, we investigated mycobacterial survival in AOs. Mtb H37Rv demonstrated a bi-phasic curve (Figure 1F), with a significant decrease of bacterial load after 7 days followed by an increase at 21 days post-infection. This suggests an early stage of bacterial control by the AO microenvironment followed by bacterial adaptation and proliferation. H37Rv∆ESX-1 presented a similar pattern of bacterial growth compared to H37Rv (Figure 1F), demonstrating that Mtb replicates in AOs irrespective of ESX-1 expression.

To determine whether AOs mounted an inflammatory/antimicrobial response to Mtb infection, we performed RT-qPCR analysis of Mtb-infected AOs 48 h post-injection focusing on cytokine, antimicrobial peptide and mucin expression (Figure 2A). Significantly induced genes included the expected IL-8 cytokine (Figure 2B)- important for immune cell chemo-attraction *in vivo*. Enhanced IL-8 secretion in the culture medium of H37Rv and H37Rv- $\Delta$ ESX-1-infected organoids was confirmed by ELISA (Figure 2C). The antimicrobial peptide  $\beta$ -

125 defensin-1 was also significantly enhanced upon Mtb H37Rv and H37Rv-∆ESX-1 126 infection (Figure 2B), which might participate in Mtb restriction during early 127 infection. Interestingly, both Mtb H37Rv and H37Rv- $\Delta$ ESX-1 significantly 128 downregulated the expression of mucins, including MUC5B and MUC4 (Figure 129 2B). Mucin expression and secretion are normally enhanced during inflammation. 130 and form part of an efficient clearance system for pathogen removal from the 131 airway (17). Downregulation of mucin expression upon Mtb infection might 132 facilitate bacilli transit through the airway to reach alveolar macrophages to 133 establish its replicative niche. For all tested genes, no significant difference was 134 observed between Mtb H37Rv and H37Rv- $\Delta$ ESX-1. The H37Rv- $\Delta$ ESX-1 mutant 135 seems to induce slightly higher expression of antimicrobial peptides  $\beta$ -defensin-1 136 and -2, cathelicidin and RNAse-7, but this difference was not statistically significant 137 (Figure 2A).

Upon Mtb infection, macrophages mount an inflammatory response 138 139 modulating the lung microenvironment (18). AOs were stimulated with the 140 supernatant of Mtb-infected human macrophages (cmMTB) and analyzed for gene 141 expression compared to stimulation with the supernatant of non-infected 142 macrophages (cmCTR). As shown in Figure 2D, among all the tested genes, the 143 expression of IL-8 and GM-CSF, major cytokines for macrophage control of Mtb 144 infection, were significantly enhanced in cmMTB-stimulated AOs compared to 145 those treated with cmCTR, mimicking the paracrine macrophage-epithelial 146 signaling occurring during lung Mtb infection. Finally, due to the essentiality of 147 macrophages in TB disease (19), we co-cultured human monocyte-derived 148 macrophages, alongside mycobacteria-injected organoids, and observed hourly

149 by confocal microscopy over the course of 4 days. Due to the complex nature of 150 this experiment, it was optimized and set up under BSL-2 conditions using *M. bovis* 151 BCG. Human macrophages were found to migrate within the collagen matrix and 152 in some instances, moved towards organoids containing mycobacteria (Movie S3). 153 Whilst we found no evidence of macrophages being able to traverse the basal side 154 and enter the organoid lumen to clear mycobacteria, we did observe some 155 macrophages capturing and ingesting bacteria close to the basal edge of the 156 organoid (Supp Figure 1B, Movie S3 & S4), resembling the natural process of 157 macrophage migration to the site of infection and bacterial clearance.

158 We have shown that mycobacteria remain viable for up to 21 days within 159 the lumen of AOs (Figure 1F) with approximately 2% of bacteria associating with 160 epithelial cells after the first week of incubation (Figure 1D). During this timeframe, while AOs integrity remains uncompromised (Figure 1C, Supp Fig 1A, Movie S2), 161 162 molecular interactions begin as early as 48 hours after injection with the 163 upregulation of cytokines and antimicrobial peptides, and the inhibition of mucins 164 (Figure 2A- C). Within 72 hours, innate immune cells can be recruited to the 165 surface of infected AOs (Supp Figure 1B, Supp Movie S3, S4). Together, these 166 data indicate that AOs can be used to study Mtb infection events such as primary 167 interactions with the airway epithelium.

The ability to model these early timeframes in a responsive, multicellular and functionally similar system to the human airway, but without the complications, monetary and ethical restrictions of animal research, is revolutionary for the TB field. The ability to further introduce human macrophages allows functional modelling of a key cell type and its cellular network, overcoming a major limitation

of organoid systems. We believe that this work forms the starting point for modelling a wide range of human respiratory pathogens, including SARS-CoV-2,

175 in AOs.

176

177 Methods

Ethic statements: The collection of patient data and tissue for AO generation was 178 performed according to the guidelines of the European Network of Research Ethics 179 180 Committees following European and national law. In the Netherlands and France, 181 the responsible accredited ethical committees reviewed and approved this study 182 in accordance with the Medical Research Involving Human Subjects Act. Human 183 lung tissue was provided by the Primary Lung Culture Facility (PLUC) at MUMC+, 184 Maastricht, The Netherlands. Collection, storage, use of tissue and patient data was performed in agreement with the "Code for Proper Secondary Use of Human 185 186 Tissue in the Netherlands" (http://www.fmwv.nl). The scientific board of the 187 Maastricht Pathology Tissue Collection approved the use of materials for this study 188 under MPTC2010-019 and formal permission was obtained from the local Medical 189 Ethical Committee (code 2017-087). The CHU of Toulouse and CNRS approved 190 protocol CHU 19 244 C and Ref CNRS 205782. All patients participating in this 191 study consented to scientific use of their material; patients can withdraw their 192 consent at any time, leading to the prompt disposal of their tissue and any derived 193 material.

Human buffy coats were obtained from volunteers with informed consent via
Sanquin (NVT0355.01) or établissement français du sang (Agreement
21PLER2017-0035AV02).

197 **Organoid culture**: AOs were derived from lung biopsies as described (6).

198 **Bacterial culture and microinjection**: DsRed-WT or -ΔESX-1 H37Rv Mtb strains 199 were obtained by complementation with the pMRF plasmid containing a DsRed 200 cassette, and were cultured in the continuous presence of 20 µg/ml of the selective 201 antibiotic hygromycin and kanamycin respectively (20). Mtb strains and *M. bovis* 202 BCG were grown and prepared for microinjection as described (18). Bacterial 203 density was adjusted to  $OD_{600} = 1$ , and phenol red added at 0.005% to visualize 204 successful microinjection (21). Injected organoids were allowed to recover for 2 h 205 at 37 °C, individually collected and re-seeded into fresh matrix for subsequent 206 analysis.

207 **Microscopy**: For time-lapse imaging, injected organoids were seeded in IBIDI 4 208 well chambers (IBIDI) and stained with CellMask™ Green Plasma Membrane 209 Stain (1/1000, Molecular Probes) for 30 min at 37°C. Organoids were washed and 210 fresh medium containing TOPRO-3 lodide (1/1000, Molecular Probes) was added. 211 Organoids were imaged using a FEI CorrSight at Maastricht University or 212 Andor/Olympus Spinning Disk Confocal CSU-X1 (10x Air 0,4 NA, 3,1 mm WD) at 213 IPBS. Z-stacks were acquired every hour for the duration of experiments and data 214 analyzed using Fiji/Image J and IMARIS.

For transmission electron microscopy (TEM), injected AO's were fixed in 4% PFA for a minimum of 3 hours at RT prior to removal from the containment lab and embedding in epon blocks as described in (22). TEM data was collected autonomously as virtual nanoscopy slides on a 120kV FEI Tecnai Spirit T12 Electron Microscope equipped with an Eagle CCD camera (23).

Colony forming unit (CFU) assay: 4 to 6 Mtb-injected organoids were collected,
washed in PBS, seeded into 24-well plates and cultured in complete AO medium
for 7–21 days. At the relevant timepoint, organoids were lysed in 100 µl of 10%
Triton X100 in water, serial dilutions were plated on 7H11 agar plates and cultured
for 3 weeks at 37 °C.

RT-gPCR: Uninfected control and Mtb-infected AO's (15 per condition) were 225 collected at 48 h post-infection, lysed in 1 ml of TRIzol Reagent (Invitrogen) and 226 227 stored at -80 °C for 2 days. As positive controls, AO's were stimulated with 0.02  $\mu$ g/ml of human IL-1 $\beta$  (Invivogen) or 0.1  $\mu$ g/ml of IFN $\gamma$  (PeproTech) for 48 h. Total 228 229 RNA was extracted using the RNeasy mini kit (Qiagen) and retrotranscribed (150 230 ng) using the Verso cDNA Synthesis Kit (Thermo Scientific). mRNA expression 231 was assessed with an ABI 7500 real-time PCR system (Applied Biosystems) and 232 the SYBRTM Select Master Mix (ThermoScientific). Relative quantification was 233 determined using the  $2^{-\Delta\Delta}Ct$  method and normalized to GAPDH. Primer 234 sequences are provided in Table 1.

Enzyme-linked immunoabsorbent assay: Between 20–30 organoids were embedded in fresh BME Cultrex and cultured with 800 μL complete media. After 48 h, supernatant was collected, sterilized through double 0.22 μm filters and stored at -80 °C until analysis. IL-8 ELISA was performed according to manufacturer instructions (Qiagen).

Flow cytometry and cell sorting: Organoids were washed out of Matrigel and dissociated into single cells using TrypLE for 5 min at 37 °C. A minimum of  $5 \times 10^5$ cells/ml were incubated with Mtb at an MOI of 10 in complete organoid media. After 4 or 24 h for single cells, or 7 days for whole intact organoids, samples were

washed with PBS, stained with CellMask Deep Red (1:30.000) and fixed in 4%
paraformaldehyde overnight at 4 °C. Cells were pelleted and resuspended in PBS
supplemented with 2% FCS. Samples were filtered just before analysis and sorted
using a BD FACS ARIA Fusion.

248 **CmMTB** preparation and Macrophage co-cultures: Monocytes were enriched 249 using RosetteSep human monocyte enrichment cocktail (Stem Cell Technologies) 250 and purified by density gradient centrifugation. Monocytes were differentiated into 251 macrophages by addition of 5 ng/ml macrophage colony stimulating factor (Sigma 252 Aldrich) for 6 days. cmCTR and cmMTB were prepared and used as previously described (18). Organoids were stained with CellMask Deep Red plasma 253 254 membrane dye as previously described, and macrophages stained with 20 µM 255 CellTracker Blue CMAC dye (ThermoFisher Scientific) for 1 h in serum-free media. Microinjected organoids and macrophages were resuspended in freshly prepared 256 257 Rat Tail Collagen type 1 (Thermofisher, 1 mg/ml) and polymerized in a 4-well, 258 glass-bottom µ-slide (Ibidi) at 37 °C for 30 min, and imaged for 96 h under a FEI 259 CorrSight microscope.

260

#### 261 Acknowledgments

Authors acknowledge C. Kuo (Stanford University, USA) for the stable expressing Rspo1-Fc cell line and the Hubrecht Institute for the stable expressing Noggin cell line; Genotoul TRI-IPBS core facility for flow cytometry and imaging, in particular Näser and E. Vega; IPBS BSL3 facilities, in particular C. Verollet for technical support. Authors also acknowledge the Microscopy CORE lab and PLUC facility at Maastricht University. This work was supported by grants from Campus France

- 268 PHC Van Gogh (40577ZE to GL-V), the Agence Nationale de la Recherche (ANR-
- 269 15-CE15-0012 (MMI-TB)) to GL-V, FRM "Amorçage Jeunes Equipes"
- 270 (AJE20151034460 to EM), ERC StG 693 (INFLAME 804249 to EM), ATIP to EM,
- ZonMW 3R's (114021005) to PJP, the Nuffic Van Gogh Programme (VGP.17/10
- to NI), and by the LINK program from the Province of Limburg, the Netherlands..
- 273

#### 274 **References**

- 2751.Houben RM & Dodd PJ (2016) The Global Burden of Latent Tuberculosis Infection: A Re-276estimation Using Mathematical Modelling. PLoS Med 13(10):e1002152 .
- 277 2. Corleis B & Dorhoi A (2020) Early dynamics of innate immunity during pulmonary
   278 tuberculosis. *Immunol Lett* 221:56-60.
- 2793.Torrelles JB & Schlesinger LS (2017) Integrating Lung Physiology, Immunology, and280Tuberculosis. Trends Microbiol 25(8):688-697.
- 2814.Fonseca KL, Rodrigues PNS, Olsson IAS, & Saraiva M (2017) Experimental study of282tuberculosis: From animal models to complex cell systems and organoids. *PLoS Pathog*28313(8):e1006421.
- 2845.Rossi G, Manfrin A, & Lutolf MP (2018) Progress and potential in organoid research. Nat285Rev Genet 19(11):671-687 .
- Sachs N, et al. (2019) Long-term expanding human airway organoids for disease modeling.
   *The EMBO journal* 38(4).
- Dutta D & Clevers H (2017) Organoid culture systems to study host-pathogen interactions.
   *Curr Opin Immunol* 48:15-22.
- 2908.Iakobachvili N & Peters PJ (2017) Humans in a Dish: The Potential of Organoids in291Modeling Immunity and Infectious Diseases. Frontiers in microbiology 8:2402.
- 2929.Pleguezuelos-Manzano C, et al. (2020) Mutational signature in colorectal cancer caused293by genotoxic pks(+) E. coli. Nature 580(7802):269-273 .
- 29410.Reuschl AK, et al. (2017) Innate activation of human primary epithelial cells broadens the295host response to Mycobacterium tuberculosis in the airways. PLoS Pathog29613(9):e1006577 .
- 29711.Ryndak MB, Singh KK, Peng Z, & Laal S (2015) Transcriptional profile of Mycobacterium298tuberculosis replicating in type II alveolar epithelial cells. *PLoS One* 10(4):e0123745 .
- 29912.Cohen SB, et al. (2018) Alveolar Macrophages Provide an Early Mycobacterium300tuberculosis Niche and Initiate Dissemination. Cell Host Microbe 24(3):439-446 e434 .
- 30113.Houben D, et al. (2012) ESX-1-mediated translocation to the cytosol controls virulence of302mycobacteria. Cell Microbiol 14(8):1287-1298.
- 30314.Tiwari S, Casey R, Goulding CW, Hingley-Wilson S, & Jacobs WR, Jr. (2019) Infect and304Inject: How Mycobacterium tuberculosis Exploits Its Major Virulence-Associated Type VII305Secretion System, ESX-1. Microbiol Spectr 7(3).
- 30615.van der Wel N, et al. (2007) M. tuberculosis and M. leprae translocate from the<br/>phagolysosome to the cytosol in myeloid cells. Cell 129(7):1287-1298 .

308	16.	Sanne van der Niet, et al. (2020) Both adaptive immunity and IL-1R1 dependent signals
309	. –	improve clearance of cytosolic virulent mycobacteria in vivo. <i>BioRxiv</i> .
310	17.	Whitsett JA & Alenghat T (2015) Respiratory epithelial cells orchestrate pulmonary innate
311		immunity. Nat Immunol 16(1):27-35.
312	18.	Lastrucci C, et al. (2015) Tuberculosis is associated with expansion of a motile, permissive
313		and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis. Cell Res
314		25(12):1333-1351 .
315	19.	Cadena AM, Flynn JL, & Fortune SM (2016) The Importance of First Impressions: Early
316		Events in Mycobacterium tuberculosis Infection Influence Outcome. mBio 7(2):e00342-
317		00316 .
318	20.	Simeone R, et al. (2015) Cytosolic access of Mycobacterium tuberculosis: critical impact
319		of phagosomal acidification control and demonstration of occurrence in vivo. PLoS
320		Pathog 11(2):e1004650.
321	21.	Bartfeld S & Clevers H (2015) Organoids as Model for Infectious Diseases: Culture of
322		Human and Murine Stomach Organoids and Microinjection of Helicobacter Pylori. J Vis
323		Exp (105).
324	22.	Lamers MM, et al. (2020) SARS-CoV-2 productively infects human gut enterocytes.
325		Science 369(6499):50-54 .
326	23.	Faas FG, et al. (2012) Virtual nanoscopy: generation of ultra-large high resolution electron
327		microscopy maps. J Cell Biol 198(3):457-469.
328		
329		
527		

#### 330 Figures

331 Figure 1. Human airway organoids (AOs) infected with Mtb. (A) Experimental 332 scheme and bright-field image of the microinjection. (B) Confocal microscopy 333 of DsRed-expressing H37Rv inside AOs, 4 days post-infection. Nuclei are labeled 334 with DAPI (blue); cellular membranes with CellMask green (green). (C) 335 Transmission electron microscopy at one week post-infection showing H37Rv 336 within the organoid lumen. Lower panels show magnifications of the boxed areas 337 in the upper image. (D) Quantification of cells associated with H37Rv after 4 (left) 338 or 24 hours (middle) incubation with AOs-derived single cells or 7 days incubation 339 in whole organoids (right) (E) Representative images of sorted epithelial cells with 340 intracellular DsRed-expressing H37Rv, scale bars =  $5\mu m$ . (F) CFU counts from 341 individual organoids on the day of microinjection (day 0), 7 and 21 days postinfection. Each dot represents one organoid. Lines indicate median CFU counts.
The experiment was performed at least four times independently. \*\*\*P < 0.001 by</li>
a two-tailed Mann-Whitney test.

345 Figure 2. Mtb-induced host responses in AOs. (A) Heat map displaying 346 modulation of cytokines, antimicrobial peptides and mucins in AOs in response to 347 mycobacterial injection (H37Rv and H37RvARD1) compared to mock-injected 348 organoids. As positive controls, AOs were treated with reconbinant IL-1 $\beta$  and 349 IFN $\gamma$ . (B) Statistically significant expression changes of IL-8,  $\beta$ -Defensin-1, MUC5B 350 and MUC4 as determined by RT-qPCR at 48 h post-infection. \*p < 0.05 by 351 Wilcoxon matched-pairs signed rank test. (C) ELISA guantification of IL-8 secretion 352 by H37Rv- or H37Rv-ΔRD1-infected AOs at 48 h post-infection. IL-8 secretion in 353 H37Rv-infected AOs was almost significantly (p=0.053 by two-tailed Wilcoxon 354 matched-pairs signed rank test), reclL-1 $\beta$ -treated AOs (reclL-1 $\beta$ ) was used as 355 positive control. (D) Statistically significant expression changes of IL-8 and GM-356 CSF as determined by RT-qPCR at 72 h after conditioning with cmCTR and 357 cmMTB, defined as conditioned media from non-infected and Mtb-infected 358 macrophages, respectively.

359

360 Supplementary Figure 1. Cell death and macrophage recruitment in
 361 mycobacteria-infected AOs. Related to Figure 1.

(A) AOs (red) were injected with PBS (as a control) or mycobacteria (green),
 stained with ToPRO3 (blue) and imaged for 4 days. ToPRO3 incorporation, and
 therefore epithelial cell death, was quantified using Fiji and plotted on the right

panel. (B) AOs microinjected with GFP-expressing *M. bovis* BCG were embedded with human monocyte-derived macrophages in collagen and imaged hourly by confocal microscopy for 5 days. AOs and macrophages were stained with CellMask Deep Red (top row) whilst macrophages were weakly stained using Cell tracker CMAC blue allowing for segmentation in IMARIS (bottom row), arrows indicate bacteria (green) passing through the epithelial cell wall (red) and interacting with macriohages (blue). Scale bar =  $20\mu m$ .

372

373 Supplementary Movie S1. Injected mycobacteria survive in the organoid

**Iumen. Related to Figure 1.** 

375 3D reconstruction of an Mtb-infected AOs 4 days post-infection. DsRed-expressing
 376 bacteria are visible in red, epithelial cell membranes are stained with Cell Mask

377 Green, and nuclei with DAPI (blue).

378

379 Supplementary Movie S2. AO infection with WT and ΔRD1 H37Rv Mtb
380 strains. Related to Figure 1.

381 Time-lapse microscopy of PBS- (left panel), H37Rv- (middle panel) and  $\Delta$ RD1 382 H37Rv- (right panel) injected organoids (stained with Cell Mask Green) over 48 383 hours.

384

Supplementary Movie S3. Macrophages are recruited to AOs for bacterial
 clearance. Related to Figure 2 and supplementary Figure 1.


- 387 Macrophages migrating to AOs in brightfield (left) and confocal microscopy (right).
- 388 AOs membranes are stained with CellMask Deep Red, mycobacteria are
- 389 expressing GFP and macrophages are stained with CellTracker CMAC blue.
- 390
- 391 Supplementary Movie S4. 3D reconstruction showing frame wise interaction
- 392 of macrophages with the AO surface and internal mycobacteria. Related to
- **Figure 2 and supplementary Figure 1.**
- 394 IMARIS rendering of supplementary movie S3 showing macrophages (blue)
- 395 migrating to organoids (red) and cleaning up bacteria (green) from within the
- 396 organoid.
- 397
- 398 Tables


Gene	Primers 5'-3'	Reference
Cytokines and chemokines		
CCL5 (NM_002985)	F- CCTCATTGCTACTGCCCTCT	In-house
	R- CGGGTGACAAAGACGACTGC	
GM-CSF (NM_000758)	F- CCTGAACCTGAGTAGAGACACT	In-house
	R- CCTTGAGCTTGGTGAGGCTG	
IL-1β (NM_000576)	F- AGCTACGAATCTCCGACCAC	In-house
	R- GGGAAAGAAGGTGCTCAGGTC	
IL-6 (NM_000600.5)	F: ACTCACCTCTTCAGAACGAATTG	PrimerBank
	R: CCATCTTTGGAAGGTTCAGGTTG	
IL-8 (NM_000584)	F- TACTCCAAACCTTTCCACCCC	In-house
	R- CTTCTCCACAACCCTCTGCA	
IP-10 (NM_001565)	F- GTGGCATTCAAGGAGTACCTC	In-house
	R- GATTCAGACATCTCTTCTCACCC	
Antimicrobial peptides		
β defensin 1 (NM_005218)	F- ATGGCCTCAGGTGGTAACTTTC	In-house
	R- GGTCACTCCCAGCTCACTTG	
β defensin 2 (NM_004942)	F-ATAGGCGATCCTGTTACCTGC	In-house
	R-CCTCCTCATGGCTTTTTGCAG	
β defensin 3 (NM_018661)	F- TGGGGTGAAGCCTAGCAG	In-house
	R- ACTTGCCGATCTGTTCCTCC	
β Defensin 4	F: TGCCGGAAGAAATGTCGCA	In-house
(NM_080389.3)	R: CGACTCTAGGGACCAGCAC	
Cathelicidin LL37	F- ATGCTAACCTCTACCGCCTCC	In-house
(NM_004345)	R- TCACCAGCCCGTCCTTCTTG	


**Table 1.** List of primers used for RT-qPCR experiments on airway organoids.

	-			
Hepcidin (NM_021175)	F- GTTTTCCCACAACAGACGGG	In-house		
	R- AGATGGGGAAGTGGGTGTC			
Lactoferrin (NM_002343)	F- CCCCTACAAACTGCGACCTG	In-house		
	R- CAGACCTTGCAGTTCGTTCAG			
RNAse 7 (NM_032572)	F- GGAGTCACAGCACGAAGACCA	In-house		
	R- GGCTTGGCACTGACTGGGATC			
Mucins				
MUC4 (NM_018406.7)	F: CTCAGTACCGCTCCAGCAG	In-house		
	R: CCGCCGTCTTCATGGTCAG			
MUC5AC	F: CCAGTCCTGCCTTTGTACGG	In-house		
(NM_001304359.2)	R: GACCCTCCTCTCAATGGTGC			
MUC5B (NM_002458.3)	F: GCCCACATCTCCACCTATGAT	PrimerBank		
	R: GCAGTTCTCGTTGTCCGTCA			
Housekeeping				
GAPDH (NM_002046)	F-CTCCAAAATCAAGTGGGGCGATG	In-house		
	R-GGCATTGCTGATGATCTTGAGGC			


# lakobachvili et al. Figure 1








## Iakobachvili et al. Figure 2



# Iakobachvili et al. Supplementary Figure 1

Α



В

